Mbm Wealth Consultants, LLC Bristol Myers Squibb CO Transaction History

Mbm Wealth Consultants, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 19, 2023	BUY	$57.89 - $64.73 $145,940 - $163,184	2,521 Added 21.41%	14,295 $829,000
Q2 2023 Jul 24, 2023	BUY	$63.71 - $70.74 $132,644 - $147,280	2,082 Added 21.48%	11,774 $752,000
Q4 2022 Feb 15, 2023	SELL	$68.48 - $81.09 $34,719 - $41,112	-507 Reduced 4.97%	9,692 $700,000
Q3 2022 Oct 24, 2022	SELL	$0.13 - $76.84 $14 - $8,375	-109 Reduced 1.06%	10,199 $719,000
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $22,730 - $25,033	313 Added 3.13%	10,308 $798,000
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $19,673 - $23,590	320 Added 3.31%	9,995 $730,000
Q4 2021 Feb 15, 2022	BUY	$53.63 - $62.52 $112,086 - $130,666	2,090 Added 27.55%	9,675 $603,000
Q3 2021 Nov 16, 2021	BUY	$59.17 - $69.31 $42,957 - $50,319	726 Added 10.58%	7,585 $449,000
Q2 2021 Aug 13, 2021	BUY	$61.91 - $67.42 $17,706 - $19,282	286 Added 4.35%	6,859 $459,000
Q1 2021 May 10, 2021	BUY	$59.34 - $66.74 $24,566 - $27,630	414 Added 6.72%	6,573 $415,000
Q4 2020 Feb 09, 2021	SELL	$57.74 - $65.43 $15,647 - $17,731	-271 Reduced 4.21%	6,159 $382,000
Q3 2020 Nov 12, 2020	BUY	$57.43 - $63.64 $47,322 - $52,439	824 Added 14.7%	6,430 $388,000
Q2 2020 Aug 07, 2020	SELL	$54.82 - $64.09 $108,708 - $127,090	-1,983 Reduced 26.13%	5,606 $330,000
Q1 2020 May 13, 2020	BUY	$46.4 - $67.43 $9,976 - $14,497	215 Added 2.92%	7,589 $423,000
Q4 2019 Feb 11, 2020	BUY	$49.21 - $64.19 $343,190 - $447,661	6,974 Added 1743.5%	7,374 $474,000
Q4 2018 Feb 13, 2019	BUY	$48.76 - $63.23 $19,504 - $25,292	400 New	400 $21,000

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Mbm Wealth Consultants, LLC, based on Form 13F filings with the SEC.

Stay updated on Mbm Wealth Consultants, LLC with notifications on news.